Medibank Private (ASX:MPL) Lifts Earnings And Dividend As Valuation Debate Intensifies
Why Medibank Private’s Latest Earnings and Dividend Matter Now
Medibank Private (ASX:MPL) has drawn fresh attention after reporting full year net income of A$638.7 million and basic earnings per share of A$0.232, alongside an increased fully franked ordinary dividend.
Medibank Private’s shares closed at A$4.78, with the stock down 7.54% on a 1 month share price basis but slightly positive over 3 months. The 3 year total shareholder return of 49.16% and 5 year total shareholder return of 63.98% point to stronger longer term momentum.
Compare Medibank Private’s earnings and dividend move with other income focused ideas by scanning the hand picked 9 dividend fortresses that also put shareholder payouts front and centre.
The share price has slipped even as Medibank Private trades below some valuation estimates and well under one intrinsic value model. How wide is the gap between today’s A$4.78 and a fair value range?
Most Popular Narrative: 25.8% Overvalued
The most followed valuation narrative on Medibank Private pegs fair value at A$3.80, which sits below the current A$4.78 share price and frames the next quote.
Medibank is Australia's largest private health insurer (≈27% share) inside a regulated, concentrated oligopoly where the top five funds hold ~79% of premium income. It is a high-quality, capital-light annuity: ~22% group ROE (~26% on underlying earnings), net cash, a fortress PHI capital position (PCA coverage ~1.9×), the lowest expense ratio in the industry (~7.6%), and a highly recurring premium base that grew through COVID and held through the 2022 cyber-crime event.
Want to see how that quality profile still leads to an overvaluation call at A$3.80 fair value? The narrative leans on specific growth, margin, and payout assumptions that sharply cap the upside implied by today’s share price.
Result: Fair Value of A$3.80 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, if Medibank Private faces tighter government control on premium increases or heavier than expected penalties from the cyber breach actions, this valuation narrative could quickly shift.
Find out about the key risks to this Medibank Private narrative.
Another View on Medibank Private’s Valuation
The SWS DCF model points in a very different direction for Medibank Private. At A$4.78, the stock is shown as trading about 32.5% below an estimated future cash flow value of A$7.08, which frames Medibank as materially undervalued on this measure. How comfortable are you relying on that single cash flow view when other signals are more cautious?
To understand how the SWS DCF model arrives at this result and what would need to change in the assumptions before that gap closes, Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Medibank Private for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 14 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of signals on Medibank Private feels balanced between concern and opportunity, take a moment to test the data and pressure test the story yourself. To weigh both sides in one place, start with the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Medibank Private?
If Medibank Private has sharpened your focus, do not stop here. Use the screeners below to uncover other stocks that could suit your portfolio goals.
- Target steady cash generators by reviewing companies with strong payouts and balance sheets through the 9 dividend fortresses.
- Hunt for potential value by scanning the 14 high quality undervalued stocks that combine quality fundamentals with prices that may lag their underlying strength.
- Prioritise resilience first and check the 13 resilient stocks with low risk scores to focus on stocks with sturdier financial and risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com